CN102680708B - Diagnostic kit and application of RNF19 (ring finger protein 19) in preparation of reagent for early diagnosis of gastric cancers - Google Patents
Diagnostic kit and application of RNF19 (ring finger protein 19) in preparation of reagent for early diagnosis of gastric cancers Download PDFInfo
- Publication number
- CN102680708B CN102680708B CN201210152712.6A CN201210152712A CN102680708B CN 102680708 B CN102680708 B CN 102680708B CN 201210152712 A CN201210152712 A CN 201210152712A CN 102680708 B CN102680708 B CN 102680708B
- Authority
- CN
- China
- Prior art keywords
- rnf19
- solution
- diagnostic kit
- serum
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the field of bioscience, in particular to a diagnostic kit and application of an RNF19 (ring finger protein 19) in preparation of a reagent for early diagnosis of gastric cancers. The diagnostic kit is used for early diagnosis of gastric cancers and comprises an ELISA (enzyme-linked immunosorbent assay) plate, a human protein RNF19, standard serums, an ELISA reagent, an enzyme substrate solution, confining liquid, sample diluent, washing liquid and stop liquid, wherein the human protein RNF19 is enveloped on the ELISA plate. Compared with the prior art, the diagnostic kit has the following advantages: 1. a sensitive, safe, reliable and easy-to-operate commercial kit is provided, is used for qualitatively determining the level of the IgA antibody against RNF19 in the human serums, and is conductive to early diagnosis of gastric cancers in an aided manner; and 2. the provided serum biomarker RNF19 has specificity of 86% and sensitivity of 86% and has the characteristics of high specificity and high sensitivity.
Description
Technical field
The present invention relates to bio-science field, particularly a kind of diagnostic kit and the RNF19 application in preparation cancer of the stomach early diagnosis reagent.
Background technology
Cancer of the stomach is the common cancer of harm humans health, and according to the World Health Organization's statistics of 2008 (World Health Organization's year statistics, 2008), in worldwide, the mortality ratio of Patients with Gastric Cancer is in second.In the statistics of WHO in 2006, show and approach 950,000 new cases, 700,000 people that simultaneously have an appointment die from this kind of disease.In China, the annual new patient's number of cancer of the stomach exceedes 300,000, dies from the number approximately 160,000 of cancer of the stomach, and case fatality rate occupies first of malignant tumour, serious threat people's life health (Chen Zhu, whole nation cause of the death Retrospect spot-check report for the third time, 2008).For reducing mortality ratio, improve the curative effect of cancer of the stomach, key is cancer of the stomach " three early " work, i.e. early detection, early diagnosis and early treatment.But, because most patients with gastric cancer lack specific clinical symptoms, therefore early carcinoma of stomach diagnosis is very low, the not enough 10%(Wu Yun of operability woods: surgery theory and practice, 2005,10:401); The life cycle of postoperative patient is also shorter.At present, overall 5 years survival rates of China's cancer of the stomach are 43.4%, postoperative pathological is (pathological TNM by stages, pTNM) I, II, III, IV phase patient's postoperative 5 years survival rates are respectively 75.65%, 58.73%, 28.01% and the bright Asia of Liu 8.42%(: Chinese Journal of Gastrointestinal Surgery, 2010,13:163).Therefore, the early diagnostic rate of raising cancer of the stomach is extremely important.And general health check-up and imaging examination effect are limited, in the time can finding and clarify a diagnosis, often in, late period, lack predictive value.Therefore, from a long-term perspective, should be devoted to find all good tumor markerses of susceptibility and specificity.In addition, heterogeneity in gastric carcinomas is large, and prognosis and larger to the reactive difference for the treatment of, for clinical assessment prognosis and the prediction to therapeutic response and evaluation, all needs good tumor markers.
Desirable tumor markers should meet following condition: (1) susceptibility is high; (2) specificity is high; (3) tumor-marker substrate concentration and tumor size, transfer, grade malignancy are relevant, can assist neoplasm staging and judging prognosis; (4) half life period short, effectively after treatment, concentration declines very soon, can comparatively fast reflect the actual conditions of in-vivo tumour; (5) be present in body fluid, particularly, in blood, be easy to detect (Liu Ping Ya: Chinese Journal of Gastrointestinal Surgery, 2010,13:163).
The research of tumour serum mark is the research emphasis of this area always.Now existing multiple cancer of the stomach tumour marker: as carcinomebryonic antigen (CEA), be present in cancer of the stomach and other gland cancer patient's serum, but less to the diagnostic significance of early carcinoma of stomach, be mainly used in dynamic observation (the Lipkin M:Cancer Research before and after curing gastric cancer, 1988,48:235; Lipkin:JBC Supplymental, 1992,16:1); The part carbohydrate antigen such as CA125, CA19-9, CA50, CA724 and CA242 can raise in part patients with gastric cancer, but only 20～40%(Kodera Y:The American journal of gastroenterology of its susceptibility, 1996,91:49; Chou M:Disease Markers, 2000,16:105;
lai IRetal:
hepato-gastroenterology, 2002,49:115; Edip U et al:Advances in Theray, 2008,25:1075); Also studies have found that tumor-associated glycoprotein antigen-72(TAG-72) be 69% to the susceptibility of cancer of the stomach, specificity is 84%(Liu Jun etc.: Chinese journals of practical medicine, 1999,15:4); Glycoprotein antigen MG7-Ag has the positive rate of 40%-60% in serum, has the positive rate (Ren J:Cancer, 2000,88:280) of 80%-94% in stomach organization; Nucleosome Histones antigen (IPO-38) is 57.4% as the susceptibility of diagnosing gastric cancer, and specificity exceedes 90%(Hao Y etal:J Proteome Res, 2008,7:3668) above these indexs are all conducive to the diagnosis of early carcinoma of stomach.Some oncogene, as DDC, c-myc, c-erb-2, p53 and nm23 etc., generation, the transfer to cancer of the stomach also has the certain significance, but is widely used in clinical still restricted (Liu Qian etc., People's Health Publisher, 2004).Due to the defect of existing cancer of the stomach biological marker in sensitivity and specificity, although there is certain value in curative effect monitoring, prompting recurrence, judging prognosis and people at highest risk's generaI investigation, still can not be used for making a definite diagnosis of cancer of the stomach at present.In order to realize the early stage high sensitivity to cancer of the stomach, the diagnosis of high specific, is badly in need of searching out more responsive, more special cancer of the stomach biomarker on molecular level.
We utilize the advantage of human protein core assembly sheet high flux, express-analysis in early-stage Study, relevant 101 parts of the serum (37 parts of Patients with Gastric Cancer, 14 parts of high risk patients, 50 parts of Healthy Human Serums) of Patients with Gastric Cancer are analyzed, compare the difference in patient and Healthy People sample within a short period of time, provide candidate's serum biomarker, to early diagnosis and effective treatment cancer of the stomach.
Albumen RNF19 (Ring Finger Protein 19) ring finger protein 19 belongs to a member of mankind Ring Finger ring finger protein family, and the assignment of genes gene mapping of this albumen of encoding is in 8q22.Most Ring family protein members are nucleoprotein, the interaction relevant (Freemont PS et al:Cell, 1991,64:483) between its zinc fingers and protein-DNA, protein-protein.RNF-19 albumen is a kind of fourth finger E3 ubiquitin ligase of the FHA/RING of comprising domain, DNA damage plays an important role in replying in early days, and and E2 ligase U bc13, the micro-point of damage at DNA is raised in the phosphorylation of the chromatin associated protein of inducing by DNA damage, the common formation that participates in K63-linked poly ubiquitin chain, main mediating protein phosphorylation and ubiquitination signal pathway.Its C end of RNF-19 albumen contains Ring-H2 zinc fingers, can be in conjunction with 2 zinc atoms.This Ring-H2 zinc finger protein may have the albumen sorting (Seol JH et al:Genes Dev, 1999,13:1614) that reaches vacuole or film by mediating protein-protein, the interaction of protein-lipid or Cell regulate effect.
At present, there are no the report using RNF19 protein as cancer of the stomach biomarker.
Summary of the invention
The first object of the present invention is to provide a kind of diagnostic kit, can not realize the technical matters of the diagnosis of early stage high sensitivity to cancer of the stomach, high specific to solve stomach cancer diagnosis reagent box of the prior art.
The second object of the present invention is to provide the application of a kind of RNF19 in preparation cancer of the stomach early diagnosis reagent, can not realize the technical matters of the diagnosis of early stage high sensitivity to cancer of the stomach, high specific to solve stomach cancer diagnosis reagent of the prior art.
The object of the invention is achieved through the following technical solutions:
A kind of diagnostic kit, for the early stage diagnosis of cancer of the stomach, described diagnostic kit comprises ELISA Plate, human protein RNF19, standard serum, enzyme marking reagent, enzyme substrate solution, confining liquid, sample diluting liquid, cleansing solution and stop buffer, wherein, described human protein RNF19 is coated in described ELISA Plate.
Preferably, described human protein RNF19 is overexpression from saccharomyces cerevisiae, affinity purification and obtaining, and concentration is 50 μ g/mL.
Preferably, described standard serum comprises 0U/mL standard serum 1 and 100U/mL standard serum 2, and described 0U/mL standard serum 1 is diluted in sample diluting liquid for Healthy Human Serum; Described 100U/mL standard serum 2 is diluted in sample diluting liquid for the positive serum of RNF19 antibody.
Preferably, described enzyme marking reagent is containing the anti-0.1-1 μ of HRP-bis-g/mL.
Preferably, described enzyme substrate solution is TMB solution, and described TMB solution comprises developer A and developer B, contains sodium acetate 13.6g, citric acid 1.6g and 30% hydrogen peroxide 0.3mL in developer A:500mL solution; In developer B:500mL solution, contain TMB 350mg, DMSO 20mL and citric acid H
2o5.1g.
Preferably, 0.01mol/L pH 7.4 phosphate-NaCl damping fluid (PBS) solution that described confining liquid is 0.5%BSA, in 1 liter of solution containing 5g BSA(bovine serum albumin(BSA)), 8g NaCl, 0.2g KH
2pO
4, 2.9g Na
2hPO
412H
2o and 0.2g KCl.
Preferably, described sample diluting liquid is 0.01mol/L pH 7.4 phosphate-NaCl damping fluid (PBS); Described cleansing solution is 0.01mol/L pH 7.4 phosphate-NaCl damping fluid (PBST), and PBST includes 0.05%Tween-20, in 1 liter of solution, contains 8g NaCl, 0.2g KH
2pO
4, 2.9g Na
2hPO
412H
2o, 0.2g KCl and 0.5mL Tween-20; Described stop buffer is 2mol/L H
2sO
4solution.
Preferably, the reagent in described kit all can add antiseptic.
A kind of diagnostic kit, for the early stage diagnosis of cancer of the stomach, what described diagnostic kit adopted is present clinical widely used elisa technique, the IgA antibody of anti-protein RNF19 in application indirect method qualitative detection human serum, specifically: with the antigen coated microwell plate of human protein RNF19, make solid phase antigen, in the micropore of envelope antigen, add test serum, again with two anti-bindings of HRP mark, form RNF19-antibody-ELIAS secondary antibody compound, after thorough washing, add substrate TMB colour developing, TMB changes into blueness under the catalysis of HRP enzyme, and under sour effect, change into final yellow, the level of the IgA antibody of the anti-protein RNF19 in the depth and the sample of color is proportionate.
The application of human protein RNF19 in preparation cancer of the stomach early diagnosis reagent.
Compared with prior art, the present invention has following advantage:
1, provide a kind of sensitive, safe, reliable, easy-operating commercial kit, the level of the IgA antibody of anti-protein RNF19 in qualitative determination human serum, contributes to auxiliary early diagnosis cancer of the stomach;
2, the specificity of the serum biomarker protein RNF19 providing is 86%, and susceptibility is 86%, has the feature of high specific and hypersensitivity.
Accompanying drawing explanation
Fig. 1 is that silver dyes the expression concentration, the schematic diagram of purified condition of identifying RNF19,
In figure:
1 represents that standard BSA solution concentration is 5 μ g/mL;
2 represent that standard BSA solution concentration is 10 μ g/mL;
3 represent that standard BSA solution concentration is 25 μ g/mL;
4 represent that standard BSA solution concentration is 50 μ g/mL;
5 represent that standard BSA solution concentration is 100 μ g/mL;
6 represent the RNF19 protein example (containing GST label) after agarose compatible medium (glutathione) (National Engineering Research Center for Biotechnology) separation and purification;
7 represent protein molecular weight marker, and molecular weight respectively from big to small: 170KD, 130KD, 95KD, 72KD, 55KD;
Fig. 2 is the expression of Western-Blotting evaluation RNF19, the schematic diagram of purified condition,
In figure:
1 represents the RNF19 protein example (containing GST label) after agarose compatible medium (glutathione) (National Engineering Research Center for Biotechnology) separation and purification;
2 represent protein molecular weight marker, and molecular weight respectively from big to small: 130KD, 95KD, 72KD, 55KD;
Fig. 3 is the concentration curve figure of the IgA antibody of anti-protein RNF19 in Healthy People, high-risk, Serum Obtained From Advance Gastric Cancer, note: the numerical value in figure is the relative level of the IgA antibody concentration of the anti-protein RNF19 in Healthy People, high-risk, each 300 parts of serum samples of patients with gastric cancer.
Embodiment
Below in conjunction with embodiment and accompanying drawing, the present invention is described further.
1, expression, purifying and evaluation RNF19:
Protein RNF19 utilizes galactose induction overexpression by the saccharomyces cerevisiae of genetic engineering modified mistake, afterwards, obtain through agarose compatible medium (glutathione) separation and purification, it is carried out to silver and dye result quantitative and that Western-Blotting identifies respectively as depicted in figs. 1 and 2.
2, the preparation of blood serum sample:
Whole blood sample in room temperature place within 2 hours or 4 ℃, spend the night after in 1000g centrifugal about 20 minutes, get supernatant and can detect immediately; Or carry out packing, and sample is put in to-20 ℃ or-80 ℃ of preservations, but should avoid multigelation.Sample after thawing should be again centrifugal, then detects.Detect in sample and can not contain NaN
3, because NaN
3suppress (HRP) activity of horseradish peroxidase.
3, the compound method of various damping fluids and reagent in ELISA method:
(1) coated damping fluid: the Na of 0.05M pH 9.6
2cO
3-NaHCO
3
(2) sample diluting liquid: pH 7.4PBS solution
(3) the PBST solution of cleansing solution: pH 7.4
(4) the pH 7.4PBS solution of confining liquid: 0.5%BSA
(5) enzyme substrate solution: developer A and developer B
(now with the current)
(now with the current)
(6) stop buffer: 2mol/L H
2sO
4solution
(timing slowly splashes into the concentrated sulphuric acid in distilled water, and limit edged mixes)
4, ELISA method is measured the concentration of the IgA antibody of anti-protein RNF19 in serum, to assist early diagnosis cancer of the stomach:
Concrete operation step is as follows:
(1) coated: the people RNF19 protein solution of purifying to be diluted to 1 μ g/mL with coated damping fluid, to join in 96 hole ELISA Plate, every hole 100 μ L, 37 ℃ of coated spending the night for 2 hours or 4 ℃; Cleansing solution is washed plate 3 times, dries.
(2) sealing: add confining liquid 200 μ L, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries.
(3) dilution of standard items and sample and application of sample: standard items and test serum sample 1:100 are diluted to 100 μ L with sample buffer, join in antigen measuring orifice plate separately.Note not having bubble, sample is added on bottom, plum target hole by application of sample, do not touch hole wall as far as possible, rocks and mix gently, adds a cover or overlay film in ELISA Plate.If test serum sample is more, suggestion is used multitube micropipet application of sample.The preparation in 15 minutes before use of standard items and detected sample, is finished and abandons, and detects next time and uses freshly prepared standard items.
(4) incubation: ELISA Plate is placed in 37 ℃ of reactions 120 minutes, gets rid of liquid in clear opening, need not wash.
(5) enzyme-added: every hole adds the anti-Human IgA antibody 100 μ L of horseradish peroxidase-labeled, 37 ℃, 60 minutes.Get rid of liquid in clear opening, the same plate of washing pats dry for 5 times.
(6) colour developing: pat dry rear each hole and first drip developer A 50 μ L, then add developer B 50 μ L, light shaking mixes, 37 ℃ of lucifuges develop the color 15 minutes.
(7) stop: sequentially every hole adds stop buffer 50 μ L, cessation reaction.The addition sequence of stop buffer should be as far as possible identical with the addition sequence of substrate solution.The substrate reactions time to after should add as early as possible stop buffer.
(8) result is judged:
I. sequentially measure the optical density (OD value) in each hole at 450nm wavelength with enzyme connection instrument.
Unit value
* A450 is the abbreviation of 450nm place absorbance.
* at present RNF19 antibody there is no the normative reference of the current international practice, has therefore adopted relative unit when this test result calibration.
Ii. the judgement of anti-RNF19 value in serum
Iii. quality control
Each testing result must meet following standard:
The A450 of standard serum 1 :≤0.100
The A450 of standard serum 2: >=0.700
As do not meet above-mentioned standard, result is considered as invalidly, must again detect.
Iv. the explanation of assay
The ROC of 50 routine Healthy Human Serums, 37 routine Serum Obtained From Advance Gastric Cancers, 14 routine high-risk patient serum is analyzed and established above reference value.
5, specificity and sensitivity Detection: adopt the serum (300 parts of patients with gastric cancer, 300 parts of people at highest risk, 300 parts of Healthy Peoples) of 900 parts of cancer of the stomach associated patient to carry out specificity and sensitivity Detection (as Fig. 3) to diagnostic kit of the present invention.The specificity of the auxiliary early diagnosis cancer of the stomach of diagnostic kit of the present invention is 86%, and susceptibility is 86%, is all much higher than the index of diagnosing gastric cancer in prior art.
The present invention also provides the new purposes of human protein RNF19 in preparation cancer of the stomach early diagnosis reagent.
Disclosed is above only several specific embodiments of the application, but the application is not limited thereto, and the changes that any person skilled in the art can think of, all should drop in the application's protection domain.
Claims (10)
1. a diagnostic kit, for the early stage diagnosis of cancer of the stomach, it is characterized in that, described diagnostic kit comprises ELISA Plate, human protein RNF19, standard serum, enzyme marking reagent, enzyme substrate solution, confining liquid, sample diluting liquid, cleansing solution and stop buffer, wherein, described human protein RNF19 is coated in described ELISA Plate, by measuring the concentration of the IgA antibody of anti-described human protein RNF19 in serum, to assist early diagnosis cancer of the stomach.
2. a kind of diagnostic kit as claimed in claim 1, is characterized in that, described human protein RNF19 is overexpression from saccharomyces cerevisiae, affinity purification and obtaining, and concentration is 50 μ g/mL.
3. a kind of diagnostic kit as claimed in claim 1, is characterized in that, described standard serum comprises 0U/mL standard serum 1 and 100U/mL standard serum 2, and described 0U/mL standard serum 1 is for being diluted in the Healthy Human Serum in sample diluting liquid; Described 100U/mL standard serum 2 is for being diluted in the positive serum of RNF19 antibody in sample diluting liquid.
4. a kind of diagnostic kit as claimed in claim 1, is characterized in that, described enzyme marking reagent is containing the anti-0.1-1 μ of HRP-bis-g/mL.
5. a kind of diagnostic kit as claimed in claim 1, it is characterized in that, described enzyme substrate solution is TMB solution, and described TMB solution comprises developer A and developer B, contains sodium acetate 13.6g, citric acid 1.6g and 30% hydrogen peroxide 0.3mL in developer A:500mL solution; In developer B:500mL solution, contain TMB350mg, DMSO20mL and citric acid H
2o5.1g.
6. a kind of diagnostic kit as claimed in claim 1, is characterized in that, 0.01mol/L pH7.4 phosphate-NaCl damping fluid that described confining liquid is 0.5%BSA contains 5gBSA, 8g NaCl, 0.2g KH in 1 liter of solution
2pO
4, 2.9g Na
2hPO
412H
20 and 0.2g KCl.
7. a kind of diagnostic kit as claimed in claim 1, is characterized in that, described sample diluting liquid is pH7.4PBS solution, in 1 liter of solution, contains 8g NaCl, 0.2g KH
2pO
4, 2.9gNa
2hPO
412H
20 and 0.2g KCl; Described cleansing solution is pH7.4PBST solution, and PBST solution includes 0.05%Tween-20, in 1 liter of solution, contains 8g NaCl, 0.2g KH
2pO
4, 2.9gNa
2hPO
412H
20,0.2g KCl and 0.5mL Tween-20; Described stop buffer is 2mol/L H
2sO
4solution.
8. a kind of diagnostic kit as claimed in claim 1, is characterized in that, the reagent in described kit all adds antiseptic.
9. a diagnostic kit, for the early stage diagnosis of cancer of the stomach, it is characterized in that, what described diagnostic kit adopted is present clinical widely used elisa technique, the IgA antibody of anti-protein RNF19 in application indirect method qualitative detection human serum, specifically: with the antigen coated microwell plate of human protein RNF19, make solid phase antigen, in the micropore of envelope antigen, add test serum, again with two anti-bindings of HRP mark, form RNF19-antibody-ELIAS secondary antibody compound, after thorough washing, add substrate TMB colour developing, TMB changes into blueness under the catalysis of HRP enzyme, and under sour effect, change into final yellow, the level of the IgA antibody of the anti-protein RNF19 in the depth and the sample of color is proportionate.
10. the application of human protein RNF19 in preparation cancer of the stomach early diagnosis reagent, by measuring the concentration of the IgA antibody of anti-described human protein RNF19 in serum, to assist early diagnosis cancer of the stomach.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210152712.6A CN102680708B (en) | 2012-05-14 | 2012-05-14 | Diagnostic kit and application of RNF19 (ring finger protein 19) in preparation of reagent for early diagnosis of gastric cancers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210152712.6A CN102680708B (en) | 2012-05-14 | 2012-05-14 | Diagnostic kit and application of RNF19 (ring finger protein 19) in preparation of reagent for early diagnosis of gastric cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102680708A CN102680708A (en) | 2012-09-19 |
| CN102680708B true CN102680708B (en) | 2014-05-21 |
Family
ID=46812951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210152712.6A Active CN102680708B (en) | 2012-05-14 | 2012-05-14 | Diagnostic kit and application of RNF19 (ring finger protein 19) in preparation of reagent for early diagnosis of gastric cancers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102680708B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107449903B (en) * | 2017-07-28 | 2019-07-05 | 上海浦东解码生命科学研究院 | Application and its kit of the IgG antibody of anti-XRCC3 as gastric cancer serum marker |
| CN107462725B (en) * | 2017-07-28 | 2019-07-05 | 上海浦东解码生命科学研究院 | Application and its kit of the IgG antibody of anti-FNDC4 as gastric cancer serum marker |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001042430A1 (en) * | 1999-12-08 | 2001-06-14 | Smithkline Beecham Corporation | Fhar1, a ring finger protein |
| CN1307050A (en) * | 2000-01-28 | 2001-08-08 | 上海博道基因技术有限公司 | Polypeptide-human zinc finger protein 19 and polynucleotide for coding said polypeptide |
| CN101258250A (en) * | 2005-07-07 | 2008-09-03 | 拜奥默里克斯股份有限公司 | Method for breast cancer diagnosis |
| KR20090063924A (en) * | 2007-12-14 | 2009-06-18 | 한국생명공학연구원 | Colon cancer diagnostic markers using up-regulated genes |
| EP2194382A1 (en) * | 2008-12-03 | 2010-06-09 | Universität des Saarlandes | An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies |
-
2012
- 2012-05-14 CN CN201210152712.6A patent/CN102680708B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001042430A1 (en) * | 1999-12-08 | 2001-06-14 | Smithkline Beecham Corporation | Fhar1, a ring finger protein |
| CN1307050A (en) * | 2000-01-28 | 2001-08-08 | 上海博道基因技术有限公司 | Polypeptide-human zinc finger protein 19 and polynucleotide for coding said polypeptide |
| CN101258250A (en) * | 2005-07-07 | 2008-09-03 | 拜奥默里克斯股份有限公司 | Method for breast cancer diagnosis |
| KR20090063924A (en) * | 2007-12-14 | 2009-06-18 | 한국생명공학연구원 | Colon cancer diagnostic markers using up-regulated genes |
| EP2194382A1 (en) * | 2008-12-03 | 2010-06-09 | Universität des Saarlandes | An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies |
Non-Patent Citations (13)
| Title |
|---|
| A Novel Centrosomal RING-Finger Protein, Dorfin, Mediates Ubiquitin Ligase Activity;Jun-ichi Niwa,et al;《Biochemical and Biophysical Research Communications》;20010331;第281卷(第3期);706–713 * |
| Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer;Cheung KF,et al;《Cancer.》;20120215;第118卷(第4期);947-959 * |
| Cheung KF,et al.Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer.《Cancer.》.2012,第118卷(第4期), |
| Jae-Won Huh，et al.Cooperative exonization of MaLR and AluJo elements contributed an alternative promoter and novel splice variants of RNF19.《Gene》.2008,第424卷(第1-2期), * |
| Jun-ichi Niwa,et al.A Novel Centrosomal RING-Finger Protein, Dorfin, Mediates Ubiquitin Ligase Activity.《Biochemical and Biophysical Research Communications》.2001,第281卷(第3期), |
| 与胃癌相关的血清学肿瘤标志物的研究进展;白雪蕾等;《世界华人消化杂志》;20051215;第13卷(第12期);1440-1444 * |
| 乳腺癌中环指蛋白5(RNF5)基因表达水平的研究;王曦等;《中国老年学杂志》;20081225;第28卷(第24期);2397-2399 * |
| 凋亡抑制蛋白Livin与胃癌的研究进展;陈鹏等;《实用医学杂志》;20081210;第24卷(第23期);3391-3392 * |
| 泛素连接酶E3和肿瘤关系的研究进展;程翌等;《实用医学杂志》;20090425;第25卷(第08期);1341-1342 * |
| 王曦等.乳腺癌中环指蛋白5(RNF5)基因表达水平的研究.《中国老年学杂志》.2008,第28卷(第24期),2397-2399. |
| 白雪蕾等.与胃癌相关的血清学肿瘤标志物的研究进展.《世界华人消化杂志》.2005,第13卷(第12期),1440-1444. |
| 程翌等.泛素连接酶E3和肿瘤关系的研究进展.《实用医学杂志》.2009,第25卷(第08期),1341-1342. |
| 陈鹏等.凋亡抑制蛋白Livin与胃癌的研究进展.《实用医学杂志》.2008,第24卷(第23期),3391-3392. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102680708A (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102680709B (en) | Diagnostic kit and application of coiled-coil domain containing protein 49 (CCDC49) in preparing gastric cancer early-stage diagnostic reagent | |
| Rho et al. | Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays | |
| CN106885908A (en) | The detection kit of blood-serum P SMD4 albumen and its detection method and application | |
| Chen et al. | Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting | |
| CN109342727B (en) | Esophageal squamous cell carcinoma autoantibody molecular marker model and application thereof | |
| Wang et al. | Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis | |
| CN110187108A (en) | A kind of autoantibody joint-detection ELISA kit for early stage cancer of the esophagus screening | |
| CN102680706B (en) | Application of protein CTSF (Cathepsin F) in preparation of reagent for diagnosing gastric cancer and diagnostic reagent kit | |
| Toyoda et al. | Novel method to measure serum levels of des‐gamma‐carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report | |
| Chen et al. | Discovery of novel protein biomarkers in urine for diagnosis of urothelial cancer using iTRAQ proteomics | |
| CN106706912A (en) | Marker for diagnosis of inflammation-associated HCC and application thereof | |
| CN110187109A (en) | A kind of autoantibody joint-detection ELISA kit for Grades of Gastric Cardia Adenocarcinoma early screening | |
| Agarwal et al. | Validation of the procalcitonin (PCT) assay: Experience in a pediatric hospital | |
| Byström et al. | Affinity proteomics exploration of melanoma identifies proteins in serum with associations to T-stage and recurrence | |
| CN107462725B (en) | Application and its kit of the IgG antibody of anti-FNDC4 as gastric cancer serum marker | |
| CN102680708B (en) | Diagnostic kit and application of RNF19 (ring finger protein 19) in preparation of reagent for early diagnosis of gastric cancers | |
| CN105092846A (en) | Application of THBS2(Thrombospondin-2) as rectal cancer serum marker and diagnostic kit | |
| CN105044360A (en) | Application of RBP4 as colorectal cancer blood serum marker and diagnostic kit | |
| CN112180103A (en) | Kit for clinically detecting active urokinase receptor in plasma of new coronary pneumonia patient | |
| CN102798722B (en) | Application of protein NT5E in preparation of reagent for diagnosing gastric cancer and diagnosis kit | |
| CN108982868A (en) | The application of nucleome Protein S P110 and kit containing the albumen in preparation alcoholic myocardiopathy early diagnosis reagent | |
| CN107449903B (en) | Application and its kit of the IgG antibody of anti-XRCC3 as gastric cancer serum marker | |
| CN102680688B (en) | Diagnostic kit and application of BFAR (bifunctional apoptosis regulator) in preparation of gastric cancer early diagnostic reagent | |
| CN102680707B (en) | Application of protein COPS2 (constitutive photomorphogenic homolog subunit 2) to preparation of reagent for diagnosing gastric cancers and diagnostic kit | |
| CN103323601B (en) | The application of S100A9 Protein Detection thing in preparation examination hepatocellular carcinoma kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU BC BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHANGHAI JIAO TONG UNIVERSITY Effective date: 20150114 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200240 MINHANG, SHANGHAI TO: 510530 GUANGZHOU, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150114 Address after: 510530 C2, building 182, science innovation building, No. 1303 science Avenue, Luogang District Science City, Guangdong, Guangzhou Patentee after: Guangzhou Bo Chong Biotechnology Co. Ltd. Address before: 200240 Dongchuan Road, Shanghai, No. 800, No. Patentee before: Shanghai Jiao Tong University |